Managing community acquired pneumonia in the elderly – the next generation of pharmacotherapy on the horizon

References

• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72.
   PubMed Web of Science ®Google Scholar
• Niederman MS Community-acquired pneumonia: the U.S. perspective. Seminars in respiratory and critical care medicine 2009; 30:179–188
   Google Scholar
• Brar NK, Niederman MS. Management of community-acquired pneumonia: a review and update. Ther Adv Respir Dis. 2011;5:61–78.
   PubMedGoogle Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, et al. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med. 2009;103:309–316.
   PubMed Web of Science ®Google Scholar
• Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiology Infection: Official Publication Eur Soc Clin Microbiol Infect Dis. 2011;17(Suppl 6):E1–59.
   PubMed Web of Science ®Google Scholar
• Dewan SK, Zheng SB, Xia SJ, et al. Senescent remodeling of the immune system and its contribution to the predisposition of the elderly to infections. Chin Med J. 2012;125:3325–3331.
   PubMed Web of Science ®Google Scholar
• Faverio P, Aliberti S, Bellelli G, et al. The management of community-acquired pneumonia in the elderly. Eur J Intern Med. 2014;25:312–319.
   PubMed Web of Science ®Google Scholar
• Meyer KC The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. Seminars in respiratory and critical care medicine 2010; 31:561–574
   Google Scholar
• Faulkner CM, Cox HL, Williamson JC. Unique aspects of antimicrobial use in older adults. Clin Infect Dis. 2005;40:997–1004.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Hartel E, Adam H, et al. Solithromycin: a novel fluoroketolide for the treatment of community-acquired bacterial Pneumonia. Drugs. 2016;76:1737–1757.
   PubMed Web of Science ®Google Scholar
• Barrera CM, Mykietiuk A, Metev H, et al. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect Dis. 2016;16:421–430.
   PubMed Web of Science ®Google Scholar
• File TM Jr., Rewerska B, Vucinic-Mihailovic V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016;63:1007–1016.
   PubMed Web of Science ®Google Scholar
• Fernandes P, Martens E, Bertrand D, et al. The solithromycin journey-it is all in the chemistry. Bioorg Med Chem. 2016;24:6420–6428.
   PubMed Web of Science ®Google Scholar
• Cooper EC, Curtis N, Cranswick N, et al. Pristinamycin: old drug, new tricks? J Antimicrob Chemother. 2014;69:2319–2325.
   PubMed Web of Science ®Google Scholar
• Koechlin C, Kempf JF, Jehl F, et al. Single oral dose pharmacokinetics of the two main components of pristinamycin in humans. J Antimicrob Chemother. 1990;25:651–656.
   PubMed Web of Science ®Google Scholar
• Tremolieres F, Mayaud C, Mouton Y, et al. [Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults]. Pathol Biol (Paris). 2005;53:503–510.
   PubMed Web of Science ®Google Scholar
• Pharmaceuticals S. Study to compare the efficacy of pristinamycin (Pyostacine ®) versus Amoxicillin in the treatment of acute community acquired pneumonia. 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02332577.
   Google Scholar
• Leclercq R, Soussy CJ, Weber P, et al. In vitro activity of the pristinamycin against the isolated staphylococci in the French hospitals in 1999-2000. Pathol Biol (Paris). 2003;51:400–404.
   PubMed Web of Science ®Google Scholar
• Qin X, Huang H. Review of nemonoxacin with special focus on clinical development. Drug Des Devel Ther. 2014;8:765–774.
   PubMedGoogle Scholar
• Guo B, Wu X, Zhang Y, et al. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Clin Drug Investig. 2012;32:475–486.
   PubMed Web of Science ®Google Scholar
• K-C S. Safety and Efficacy Study of TG-873870 (Nemonoxacin) in diabetic foot infections. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT00685698.
   Google Scholar
• Cheng S, Wu R, Hsu Z, et al. Efficacy and safety of oral nemonoxacin in treatment of community-acquired pneumonia: subgroup analysis results in taiwanese patients in a randomized, double-blind, multi-center, phase III comparative study with levofloxacin. 2015. Available at: www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A4063.
   Google Scholar
• TaiGen Biotechnology. A phase III study to evaluate the efficacy and safety of intravenous infusion of nemonoxacin in treating CAP. 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02205112.
   Google Scholar
• Van Rensburg DJ, Perng RP, Mitha IH, et al. Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Antimicrob Agents Chemother. 2010;54:4098–4106.
   PubMed Web of Science ®Google Scholar
• Poole RM. Nemonoxacin: first global approval. Drugs. 2014;74:1445–1453.
   PubMed Web of Science ®Google Scholar
• Sader HS, Paukner S, Ivezic-Schoenfeld Z, et al. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012;67:1170–1175.
   PubMed Web of Science ®Google Scholar
• Rubino CM, Xue B, Bhavnani SM, et al. Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59:282–288.
   PubMed Web of Science ®Google Scholar
• Prince WT, Ivezic-Schoenfeld Z, Lell C, et al. Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013;57:2087–2094.
   PubMed Web of Science ®Google Scholar
• Study PW Comparing the safety and efficacy of two doses of BC-3781 vs Vancomycin in patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI). 2012. Available at: https://clinicaltrials.gov/ct2/show/NCT01119105.
   Google Scholar
• Seltzer E Study to compare Lefamulin to Moxifloxacin (with or without linezolid) for the Treatment of Adults with Pneumonia (LEAP). 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02559310.
   Google Scholar
• Gasink L. Study to compare Lefamulin to Moxifloxacin for the Treatment of Adults with Pneumonia (LEAP2). 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02813694.
   Google Scholar
• Eyal Z, Matzov D, Krupkin M, et al. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep. 2016;6:39004.
   PubMed Web of Science ®Google Scholar
• Paukner S, Riedl R. Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance. Cold Spring Harb Perspect Med. 2016;7:a027110.
   Web of Science ®Google Scholar
• Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58:1127–1135.
   PubMed Web of Science ®Google Scholar
• Villano S, Steenbergen J, Loh E. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol. 2016;11:1421–1434.
   PubMed Web of Science ®Google Scholar
• Tanaka SK, Villano S. In vitro and in vivo assessments of cardiovascular effects with omadacycline. Antimicrob Agents Chemother. 2016;60:5247–5253.
   PubMed Web of Science ®Google Scholar
• Flarakos J, Du Y, Gu H, et al. Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline. Xenobiotica. 2016;47(8):682–696.
   PubMed Web of Science ®Google Scholar
• Paratek P Omadacycline. 2017. Available at: http://paratekpharma.com/science/omadacycline/
   Google Scholar
• Pharmaceuticals P. Omadacycline vs moxifloxacin for the treatment of CABP. 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02531438
   Google Scholar
• Kisgen J, Whitney D. Ceftobiprole, a broad-spectrum cephalosporin with activity against Methicillin-Resistant Staphylococcus aureus (MRSA). P T. 2008;33:631–641.
   PubMedGoogle Scholar
• Liapikou A, Cilloniz C, Torres A. Ceftobiprole for the treatment of pneumonia: a European perspective. Drug Des Devel Ther. 2015;9:4565–4572.
   PubMedGoogle Scholar
• Nicholson SC, Welte T, File TM, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39:240–246.
   PubMed Web of Science ®Google Scholar
• Van Bambeke F. Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol. 2015;10:1111–1123.
   PubMed Web of Science ®Google Scholar
• Kocsis B, Domokos J, Szabo D. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann Clin Microbiol Antimicrob. 2016;15:34.
   PubMed Web of Science ®Google Scholar
• O’Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67–73.
   PubMed Web of Science ®Google Scholar
• Melinta Therapeutics Inc. Study to compare delafloxacin to moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT02679573
   Google Scholar
• Candel FJ, Penuelas M. Delafloxacin: design, development and potential place in therapy. Drug Des Devel Ther. 2017;11:881–891.
   PubMed Web of Science ®Google Scholar